NASDAQ:IBRX ImmunityBio (IBRX) Stock Price, News & Analysis $8.14 -0.23 (-2.75%) Closing price 09/15/2026 04:00 PM EasternExtended Trading$8.09 -0.05 (-0.60%) As of 04:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ImmunityBio Stock (NASDAQ:IBRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ImmunityBio alerts:Sign Up Key Stats Today's Range$7.85▼$8.3450-Day Range$6.83▼$8.8752-Week Range$1.95▼$12.43Volume8.93 million shsAverage Volume7.95 million shsMarket Capitalization$8.63 billionP/E RatioN/ADividend YieldN/APrice Target$14.20Consensus RatingModerate Buy Company Overview ImmunityBio, Inc. is a biotechnology company focused on developing and commercializing immunotherapies and other treatments designed to activate the immune system against cancer and infectious diseases. The company’s platform combines biologics, cell therapies, vaccines and other approaches intended to generate durable immune responses. Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist designed to stimulate natural killer cells and T cells. In 2024, the U.S. Food and Drug Administration approved ANKTIVA in combination with Bacillus Calmette-Guérin for certain adults with BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors. ImmunityBio is also evaluating ANKTIVA and other investigational therapies in additional cancer settings. ImmunityBio’s development programs have included cancer vaccines, engineered cell therapies and combination regimens intended to address solid tumors and other serious diseases. The company conducts clinical development and commercial activities primarily in the United States, while its therapies have been studied through international research programs. Patrick Soon-Shiong, M.D., is the company’s founder and executive chairman and has served as its chief executive officer.AI Generated. May Contain Errors. Read More ImmunityBio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreIBRX MarketRank™: ImmunityBio scored higher than 41% of companies evaluated by MarketBeat, and ranked 657th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingImmunityBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialImmunityBio has a consensus price target of $14.20, representing about 74.4% upside from its current price of $8.14.Amount of Analyst CoverageImmunityBio has only been the subject of 1 research reports in the past 90 days.Read more about ImmunityBio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ImmunityBio are expected to grow in the coming year, from ($0.44) to ($0.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmunityBio is -8.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmunityBio is -8.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about ImmunityBio's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted34.97% of the float of ImmunityBio has been sold short.Short Interest Ratio / Days to CoverImmunityBio has a short interest ratio ("days to cover") of 14.77, which indicates bearish sentiment.Change versus previous monthShort interest in ImmunityBio has recently decreased by 1.46%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunityBio does not currently pay a dividend.Dividend GrowthImmunityBio does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment0.07 News SentimentImmunityBio has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for ImmunityBio this week, compared to 9 articles on an average week.Search InterestOnly 18 people have searched for IBRX on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat Follows19 people have added ImmunityBio to their MarketBeat watchlist in the last 30 days. This is an increase of 58% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ImmunityBio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,753,442.00 in company stock.Percentage Held by Insiders66.10% of the stock of ImmunityBio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions8.58% of the stock of ImmunityBio is held by institutions.Read more about ImmunityBio's insider trading history. Receive IBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunityBio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IBRX Stock News HeadlinesImmunityBio (IBRX) Moved, So What Is Drawing Fresh Attention?4 hours ago | finance.yahoo.comSLS, IBRX stocks draw investor attention with major cancer conferences and new drug data on deckSeptember 14 at 8:17 AM | msn.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery. | Behind the Markets (Ad)IBRX stock eyes worst week since July: New patent eyes broader Anktiva use ahead of lung cancer conferenceSeptember 11, 2026 | msn.comSLS, IBRX in focus: Canadian insurance giant Manulife’s unit raises stakes ahead of key cancer catalystsSeptember 10, 2026 | msn.comImmunityBio (IBRX) Gets a Buy from Piper SandlerSeptember 9, 2026 | theglobeandmail.comImmunityBio: None Of The Moonshots Is Priced InSeptember 3, 2026 | seekingalpha.comSLS, IBRX stocks post August gains: Eli Lilly’s latest $2.9B deal has retail traders bracing for an 'M&A rampage'September 1, 2026 | msn.comSee More Headlines IBRX Stock Analysis - Frequently Asked Questions How have IBRX shares performed this year? ImmunityBio's stock was trading at $1.98 at the beginning of 2026. Since then, IBRX stock has increased by 311.1% and is now trading at $8.14. How were ImmunityBio's earnings last quarter? ImmunityBio, Inc. (NASDAQ:IBRX) announced its quarterly earnings data on Tuesday, August, 4th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.14. The business had revenue of $51.24 million for the quarter, compared to the consensus estimate of $49.70 million. When did ImmunityBio IPO? ImmunityBio (IBRX) raised $205 million in an initial public offering on Tuesday, July 28th 2015. The company issued 9,531,200 shares at $20.00-$23.00 per share. Who are ImmunityBio's major shareholders? Top institutional investors of ImmunityBio include BlackRock Inc. (3.22%), Bank of America Corp DE (0.21%), Bank of New York Mellon Corp (0.13%) and Squarepoint Ops LLC (0.07%). Insiders that own company stock include Barry J Simon, Cheryl Cohen and Christobel Selecky. View institutional ownership trends. How do I buy shares of ImmunityBio? Shares of IBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ImmunityBio own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunityBio investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Home Depot (HD), Alphabet (GOOG) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings8/04/2026Today9/16/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (8m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 IBRX's financial health is in the Green zone, according to TradeSmith. IBRX has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IBRX CIK1326110 Webimmunitybio.com Phone(844) 696-5235FaxN/AEmployees691Year Founded2014Price Target and Rating Average Price Target for ImmunityBio$14.20 High Price Target$23.00 Low Price Target$9.00 Potential Upside/Downside+74.4%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$351.40 million Net Margins-598.55% Pretax Margin-598.69% Return on EquityN/A Return on Assets-51.65% Debt Debt-to-Equity RatioN/A Current Ratio5.72 Quick Ratio5.70 Sales & Book Value Annual Sales$113.29 million Price / Sales76.15 Cash FlowN/A Price / Cash FlowN/A Book Value($0.51) per share Price / Book-15.96Miscellaneous Outstanding Shares1,059,840,000Free Float359,284,000Market Cap$8.63 billion OptionableOptionable Beta0.04 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:IBRX) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our PartnersThis Microcap Is Taking On the Energy Industry’s Dirtiest ProblemsA small company has developed water-based cleaning technologies aimed at some of heavy industry's toughest pro...Wall Street Logic | Sponsored“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...Brownstone Research | SponsoredThe national debt just passed $39 trillionThe U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40...US Gold Bureau | SponsoredJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...Banyan Hill Publishing | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...Porter & Company | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
